The Polio Eradication and Endgame Strategic Plan
Part 1: Technical Rationale for IPV Introduction and OPV Withdrawal
GPEI Accomplishment Significant Decline in Paralysis Due
to WPVs, 1988 to 2013*
Poliovirus Types
IPV
Number of Cases of cVDPV-related Polio Exceeds the Number of Cases
of WPV
Polio Eradication and Endgame Strategic Plan 2013 to 2018
Polio Eradication and Endgame Strategic Plan
Objectives
Objective 2 Strengthen Immunization Systems, Introduce
IPV, and Withdraw OPV
SAGE Recommendations for the Planned Use of IPV
Introducing at Least 1 Dose of IPV Before the tOPV → bOPV Switch
Rationale: Improve Global Population Immunity
Individual Protection Against IPV-induced Paralytic Disease
Reducing the Risks
Individual Protection Against IPV-induced Paralytic Disease
Reducing the Risks
Individual Protection Against IPV-induced Paralytic Disease
Reducing the Risks
Poliovirus Shedding in IPV vs OPV After Virus Vaccine Challenge
IPV and Polio Eradication
Recommended IPV ScheduleKey Points
Programmatic Implications of IPV Introduction
Global Introduction of IPV
Introducing IPV in 124 CountriesA Coordinated, Multipartner Effort
IPV Vaccine DemandForecast and Supply
IPV Presentations and Formulations
IPV Prices for Supply Through UNICEF (2014 to 2018)
GAVI Support for IPVGAVI Alliance Board of Director Decisions, November
2013*
Administration of IPV
Advantages of Administering Multiple Injections at Same Visit
IPV Is Temperature Sensitive
IPV Impact of 1-dose Vial on Central-level Cold Chain in DR
Congo Is Limited
IPV Multidose Vials
Technical and Communication Resources for Planning and IPV
Introduction
Considerations for Planning and LogisticsSummary
Abbreviations
Abbreviations (cont)
References
References (cont)
References (cont)